CYB-004 is under clinical development by Cybin and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase I drugs for Generalized Anxiety Disorder (GAD) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CYB-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CYB-004 overview

CYB-004 is under development for the treatment of social anxiety disorder and generalized anxiety disorder. It is administered through inhalation route, intravenous bolus and intravenous route. The drug candidate is a deuterated forms of DMT and 5-MeO-DMT. It is a deuterated tryptamine and acts by targeting 5-hydroxytryptamine receptor 2A. 

Cybin overview

Cybin is a clinical-stage biopharmaceutical company that develops psychedelic drugs to treat mental health conditions. The company’s pipeline products include CYB003, CYB004 and CYB005. Its CYB003 is a deuterated psiloCybin analog that treats major depressive disorder and alcohol use disorder; CYB004 is a deuterated dimethyltryptamine that treats generalized anxiety disorder. Cybin’s CYB005 is a phenethylamine derivative that treats neuroinflammation. The company works in partnership with Clinilabs Drug Development Corporation, the University of Washington and Greenbrook TMS. The company operates in Canada and the US. Cybin is headquartered in Toronto, Ontario, Canada.

For a complete picture of CYB-004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.